XTMAB-16 for Sarcoidosis

Recruiting in Palo Alto (17 mi)

+6 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Xentria, Inc.

No Placebo Group

Prior Safety Data

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

Eligibility Criteria

This trial is for patients with pulmonary sarcoidosis who completed the XTMAB-16-201 study. They should have finished either Week 12 or Week 24 assessments and must be on a stable steroid dose for at least two weeks before starting this extension study.

Inclusion Criteria

I completed Week 12 or 24 assessments in the XTMAB-16-201 study.

I have been on a stable steroid dose for at least 2 weeks before joining this part of the study.

Participant Groups

The trial is testing the long-term safety and effectiveness of a drug called XTMAB-16 in treating pulmonary sarcoidosis, which may also affect other parts of the body. It's an open-label extension, meaning everyone knows they're getting XTMAB-16.

1Treatment groups

Experimental Treatment

Group I: XTMAB-16 TreatmentExperimental Treatment1 Intervention

Dose to be established in the XTMAB-16-201 Study.

XTMAB-16 is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as XTMAB-16 for: